Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford Sells 1,817 Shares

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) COO Kathleen Ford sold 1,817 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $14,299.79. Following the sale, the chief operating officer now owns 21,367 shares in the company, valued at $168,158.29. The trade was a 7.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Kathleen Ford also recently made the following trade(s):

  • On Monday, November 18th, Kathleen Ford sold 526 shares of Kura Oncology stock. The stock was sold at an average price of $16.03, for a total transaction of $8,431.78.

Kura Oncology Stock Down 1.8 %

Shares of NASDAQ:KURA opened at $7.77 on Wednesday. Kura Oncology, Inc. has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market cap of $604.20 million, a P/E ratio of -3.29 and a beta of 0.81. The firm has a fifty day moving average price of $9.23 and a 200 day moving average price of $15.69.




Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter last year, the company posted ($0.50) EPS. Sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

KURA has been the subject of several recent analyst reports. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Lifesci Capital raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, October 22nd. JMP Securities reiterated a "market outperform" rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. HC Wainwright boosted their target price on Kura Oncology from $32.00 to $37.00 and gave the stock a "buy" rating in a research note on Thursday, November 21st. Finally, Stifel Nicolaus lowered shares of Kura Oncology from a "buy" rating to a "hold" rating and dropped their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.38.

Read Our Latest Analysis on Kura Oncology

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KURA. Jennison Associates LLC purchased a new stake in shares of Kura Oncology during the fourth quarter worth approximately $623,000. China Universal Asset Management Co. Ltd. increased its stake in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock valued at $144,000 after buying an additional 1,750 shares during the period. Moody Aldrich Partners LLC raised its position in Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after buying an additional 42,712 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the 4th quarter worth $436,000. Finally, Harbor Capital Advisors Inc. raised its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after purchasing an additional 2,076 shares during the last quarter.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Featured Stories

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

Insider Buying or Selling at Kura Oncology?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Kura Oncology and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles